OmniAb Expands Partner Base but Faces Revenue Decline in 2025
Event summary
- OmniAb ended 2025 with 107 active partners and 407 active programs, up from previous periods.
- Revenue declined to $8.4M in Q4 2025 from $10.8M in Q4 2024 due to lower license and service revenue.
- Net loss for 2025 was $64.8M, slightly worse than the $62.0M loss in 2024.
- OmniAb launched OmniUltra™, a transgenic chicken technology for antibody discovery.
- The company expects 2026 revenue between $25M and $30M, with cash reserves dropping to $30M–$35M.
The big picture
OmniAb's strategic focus on expanding its partner base and launching innovative technologies like OmniUltra™ reflects broader trends in the biotech sector toward collaborative drug discovery. However, the company faces challenges in maintaining revenue growth amid declining license income, highlighting the need for sustainable monetization of its pipeline. The industry-wide shift toward outsourced antibody discovery services positions OmniAb as a key player, but execution risks remain.
What we're watching
- Revenue Diversification
- How OmniAb will balance declining license revenue with growing milestone and royalty income.
- Cost Management
- Whether the company can sustain its disciplined cost structure amid expanding partner programs.
- Technology Adoption
- The pace at which OmniUltra™ and picobodies™ gain traction in the biotech industry.
Our editorial coverage:
Related topics